Drugs / TB-840
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05045534 | Sep 2021 → Aug 2022 | — | Therasid Bioscience | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TB-840 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05045534 ↗ |
| Action | Activate | “activates RORα(Retinoid-related orphan receptor)” NCT05045534 ↗ |
| Route | Oral | “After Oral Administration” NCT05045534 ↗ |
| Target | RORA | “activates RORα(Retinoid-related orphan receptor)” NCT05045534 ↗ |